TUKYSA under the microscope: how safe is it in everyday use?
NCT ID NCT06873191
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tracks 600 adults in Korea with advanced HER2-positive breast cancer who are starting TUKYSA for the first time. Researchers will monitor how well the drug works and any side effects in real-world settings, outside of controlled trials. The goal is to confirm the drug's safety and effectiveness as part of a required post-approval review.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TUKYSA (tucatinib)
- What this could lead to
- If successful, this study will confirm that TUKYSA works safely in everyday clinical practice, supporting its continued use for advanced HER2+ breast cancer.
- What could go wrong
- This is an observational study, not a new treatment test. It only monitors existing use, so it won't discover new cures or major breakthroughs. Results may be limited to Korean patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE LOCALLY ADVANCED UNRESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Could a personal coach at home boost energy for cancer patients?
- Can an immune booster help chemotherapy fight metastatic breast cancer?
- Can a Four-Drug cocktail tame a tough breast cancer?
- Can a new drug outsmart resistant breast cancer?